Immune response to ovarian cancer may predict survival, Mayo-led study findsOctober 12, 2017
ROCHESTER, Minn. - A group of international cancer researchers led by investigators from Mayo Clinic and University of New South Wales Sydney has found that the level of a type of white blood cell, called tumor-infiltrating lymphocytes, present in the tumors of patients with high-grade ovarian cancer may predict a patient's survival. Results of the study by the Ovarian Tumor Tissue Analysis Consortium were published today in JAMA Oncology.
"We know that a type of tumor-infiltrating lymphocyte called cytotoxic CD8 are present in the tumors of patients with high-grade ovarian cancer," says Matthew Block, M.D., Ph.D., a Mayo Clinic oncologist who co-led the research team with Ellen Goode, Ph.D., of the Mayo Clinic Cancer Center Genetic Epidemiology and Risk Assessment Program. "However, little was known about the role in fighting high-grade ovarian cancer, compared to other clinical factors."
To help answer this question, researchers studied more than 5,500 patients from nine different countries, including 3,196 with high-grade ovarian cancer. Researchers found that patients with high-grade ovarian cancer showed the most infiltration with tumor-infiltrating lymphocytes, which were associated with longer overall survival.
"This study shows the higher the level of cytotoxic CD8 tumor-infiltrating lymphocytes in a tumor, the better the survival for patients with high-grade ovarian cancer," says Dr. Block. "Developing a better understanding of factors that increase cytotoxic CD8 tumor-infiltrating lymphocytes will be the key to developing treatments to achieve better outcomes in treating patients with high-grade ovarian cancer.
"This is by far the largest study of this type and would not have been possible without scientists from North and South America, Europe and Australia all working together," says Susan Ramus, Ph.D., University of New South Wales Sydney.
As a leading institution funded by the National Cancer Institute, Mayo Clinic Cancer Center conducts basic, clinical and population science research, translating discoveries into improved methods for prevention, diagnosis, prognosis and therapy. For information on cancer clinical trials, call the Clinical Trial Referral Office at 1-855-776-0015 (toll-free).
About Mayo Clinic
Mayo Clinic is a nonprofit organization committed to clinical practice, education and research, providing expert, comprehensive care to everyone who needs healing. For more information, visit mayoclinic.org/about-mayo-clinic or newsnetwork.mayoclinic.org.
Related Tumors Articles:
An analysis of breast cancer data revealed that many small breast cancers have an excellent prognosis because they are inherently slow growing, according to Yale Cancer Center experts.
An IDIBELL research team manages to characterize the complete epigenomes of the most frequent tumors, including those of colon, lung and breast cancer.
Rakesh Jain, Ph.D., Director of the Edwin L. Steele Laboratory for Tumor Biology at the Massachusetts General Hospital and supported by the National Foundation for Cancer Research, has discovered a novel mechanism behind the resistance to HER2- or PI3K-targeted therapies, and a treatment strategy that may overcome treatment resistance.
MIT engineers have developed a highly sensitive way to reveal ovarian tumors: In tests in mice, they were able to detect tumors smaller than 2 millimeters in diameter.
Dr. Amanda Paulovich, whose lab has a leading role in the Beau Biden Cancer Moonshot, will speak April 5 at the AACR annual meeting about her lab's pioneering methods to measure proteins that serve as tumor markers.
A new research analysis provides physicians and patients with new information to help them make difficult decisions about how to treat tumors and infections.
A new active pharmaceutical ingredient may help against severe forms of testicular cancer, which only respond inadequately to other therapies.
Immunotherapy is a new and highly promising form of treatment for cancer, but in many patients, tumors recur.
Scientists of Helmholtz Zentrum München and the Munich University Hospital (LMU) are developing a novel antibody to treat brain tumors.
A recent study reported in the May issue of the Journal of Nuclear Medicine demonstrates that Ga-68 DOTATATE PET/CT scans are superior to In-111 pentetreotide scans, the current imaging standard in the United States for detecting neuroendocrine tumors, and could significantly impact treatment management.
Related Tumors Reading:
Tumor (Object Lessons)
by Anna Leahy (Author), Christopher Schaberg (Series Editor), Ian Bogost (Series Editor)
Object Lessons is a series of short, beautifully designed books about the hidden lives of ordinary things.
One in two men and one in three women will develop invasive cancer. Tumors have the power to redefine identities and change how people live with one another.
Tumor takes readers on an intellectual adventure around the attitudes that shape how humans do scientific research, treat cancer, and talk about disease, treatment, and death. With poetic verve and acuity, Anna Leahy explores why and how tumors happen, how we think and talk about them, and how we try to rid... View Details
Tumors in Domestic Animals
by Donald J. Meuten (Editor)
Tumors in Domestic Animals, Fifth Edition is a fully revised new edition of the most comprehensive and authoritative reference on veterinary tumor pathology in common domestic animals, now in full color throughout with the most current advances in research and diagnostics.Now in full color with hundreds of exquisite new images showing diagnostic features, pathogenesis, and techniques Adds new sections on relevant clinical pathology and oncology Updated throughout to include the very latest advances in research and diagnostics Takes a logical, user-friendly system approach... View Details
The Tumor: A Non-Legal Thriller
Imaging of Soft Tissue Tumors
by Mark Kransdorf (Author), Mark D. Murphey MD (Author)
Imaging of Soft Tissue Tumors, Third Edition
Imaging technology plays an essential role in the diagnosis of soft tissue tumors as well as in surgical planning. Not only can imaging studies such as CT and MRI determine the relationship between a tumor and adjacent vessels and nerves, but, because some soft tissue tumors possess specific radiologic presentations, imaging can help pinpoint the tumor type.
Based on cases seen at the Armed Forces Institute of Pathology and the Mayo Clinic, this comprehensive reference offers detailed visually supported information on the... View Details
Enzinger and Weiss's Soft Tissue Tumors: Expert Consult: Online and Print, 6e
by John R. Goldblum MD FCAP FASCP FACG (Author), Sharon W. Weiss MD (Author), Andrew L. Folpe MD (Author)
Enzinger and Weiss's Soft Tissue Tumors is your essential medical reference on the diagnosis of tumors of the skeletal muscles, connective tissue, fat, and related structures. No other source matches Enzinger and Weiss’s scope and depth of coverage in this complex and challenging area of surgical pathology, and no other text contains as much practical information on differential diagnosis. Microscopic findings are correlated with the latest developments in molecular biology, cytogenetics, and immunohistochemistry, providing you with a comprehensive... View Details
Tumors of the Bone Marrow (Atlas of Tumor Pathology, Series 4)
by Kathryn Foucar (Author)
Tumors of the Thyroid Glands (Atlas of Tumor Pathology)
by American Registry of Pathology (Corporate Author)
In the years since the publication of the Third Series AFIP Fascicles on the thyroid and parathyroid glands, awareness of the remarkable morphologic diversity of thyroid carcinoma has notably expanded, and great advances have been made in unraveling the molecular genetic features of thyroid and parathyroid tumors. There has also been an increased interest in the use of the fine-needle aspiration technique for the diagnosis and management of thyroid tumors, and in the role of the pathologist in the operative handling of the hyperfunctioning parathyroid gland. This Fascicle documents the most... View Details
Tumors of the Soft Tissue (Atlas of Tumor Pathology)
by American Registry of Pathology (Corporate Author)
This volume follows the long tradition of AFIP Atlases of Tumor Pathology. The authors have put emphasis on diagnosis, so the presentation is generally concise, yet more comprehensive on key points. In addition, the authors emphasize diagnostically important information on immunohistochemistry and molecular genetics, and include additional details when biologically significant. Site-specific soft tissue entities covered in the other atlases are often excluded due to space constraints. The text is aimed as a practical diagnostic aid for pathologists, cytopathologists and pathology trainees,... View Details
Biopsy Interpretation of Soft Tissue Tumors (Biopsy Interpretation Series)
by Cyril Fisher MD (Editor), Elizabeth Montgomery MD (Editor), Khin Thway BSc MBBS FRCPath (Editor)
Part of the popular Biopsy Interpretation Series, the second edition of Biopsy Interpretation of Soft Tissue Tumors provides an easy-to-follow, practical approach to the interpretation of soft tissue biopsies, including open and percutaneous core needle biopsies. Covering both common and rare soft tissue tumors, this up-to-date bench reference parallels the diagnostic process, detailing key differential diagnostic features of specific tumors using morphologic, immunohistochemical, ultrastructural, and genetic data. A pattern-based approach ensures that you can quickly find the... View Details
Cancer is a Fungus: A Revolution in Tumor Therapy
by Dr. T. Simoncini (Author)
Book describes how a fungous infection always forms the basis of every neoplastic formation, and this formation tries to spread within the whole organism without stopping. At the moment the constant, uniform, and implacable growth of a tumor is in no way affected by current oncological treatments. A recovery rate for cancer that fluctuates at around 7% is mentioned in the classical books and treatises in spite of all the tricks and distortion of statistics. After making the necessary corrections, this amounts to virtually nil. The rest is propaganda for orthodox oncology. On the basis of the... View Details